Rezolute, Inc. (RZLT) Stock Price & Analysis
Rezolute, Inc. (RZLT) closed at USD 4.22 on Wednesday, October 28, 2026, up 2.68% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.11; the Oct 28, 2026 session ranged USD 4.02–4.24 on volume of 1,414,466 shares. Market capitalization is $408.17M, with a 52-week range of USD 1.07–11.46 (NCM). Source: Nexqual, retrieved October 29, 2026 at 07:33 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RZLT.md
Key facts (RZLT)
- Analysts: Buy (mean 1.82 on a 1–5 scale) (11 analysts), mean target USD 9.8 (range 6–15).
- Total return with dividends: 1Y -55.7% vs S&P 500 +13.6%; 5Y -34.1% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.19, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RZLT)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$41.8M | -$56.0M | -$70.4M | -$79.9M | -$83.0M | -$83.0M |
| Net income | -$41.1M | -$51.8M | -$68.5M | -$74.4M | -$77.6M | -$77.6M |
| EPS (diluted) | -$2.32 | -$1.01 | -$1.33 | -$0.98 | -$0.75 | — |
| Free cash flow | — | -$44.6M | — | — | — | — |
| Cash + short-term investments | $150M | $102M | $127M | $168M | $108M | — |
Fiscal years end Jun. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (RZLT)
P/B 4.0x · Earnings yield -19.01%
Analysts (RZLT)
Consensus Buy (mean 1.82 on a 1–5 scale), 11 analysts; mean target USD 9.8 (low 6, high 15).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | Lake Street | Target raised | Buy | $9 → $12 |
| 2026-10-06 | Citizens | Target raised | Market Outperform | $11 → $15 |
| 2026-10-06 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | |
| 2026-09-30 | Lake Street | Initiated | Buy | $9 |
| 2026-09-29 | Craig-Hallum | Upgrade | Hold → Buy | $4 → $7 |
| 2026-09-25 | HC Wainwright & Co. | Target raised | Buy | $5 → $10 |
Total return (dividends reinvested) (RZLT)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -55.7% | -34.1% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -55.8% | -8.0% |
| Volatility (annualized) | 225.4% | 118.4% |
| Max drawdown | -87.2% (Dec 2025→Dec 2025) | -88.3% (Nov 2021→Nov 2023) |
RZLT earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.20 | −$0.14 | Miss −42.9% | — |
| — | Quarter ended Dec 31, 2025 | −$0.22 | −$0.18 | Miss −22.2% | — |
| — | Quarter ended Sep 30, 2025 | −$0.18 | −$0.26 | Beat +30.8% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
RZLT recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 28, 2026 | Schedule 13G | Jennison Associates LLC: 5.5% of shares, passive 5%+ holder |
| Oct 21, 2026 | DEF 14A | Proxy statement (pay, board, votes) · period ended Dec 2, 2026 |
| Oct 14, 2026 | 8-K | Regulation FD disclosure |
| Oct 5, 2026 | 8-K | Regulation FD disclosure |
| Sep 24, 2026 | 10-K | Annual report · period ended Jun 30, 2026 |
| Sep 24, 2026 | 8-K | Quarterly results |
| Aug 14, 2026 | Schedule 13G/A | BALYASNY ASSET MANAGEMENT L.P., BAM GP LLC: 4.8% of shares, passive 5%+ holder (amended) |
| Aug 12, 2026 | Schedule 13G/A | BANK OF AMERICA CORP /DE/: 1.2% of shares, passive 5%+ holder (amended) |
| Aug 12, 2026 | Schedule 13G | Dellora Investments Master Fund LP, Dellora Investments LP: 5.9% of shares, passive 5%+ holder |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
RZLT suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | ActiveSite Pharmaceuticals | “Our most significant long-term contractual obligations consist of $25.0 million payable upon regulatory approval for ersodetug by any regulatory authority under the Ersodetug Licensing Agreement (as defined below), and additional clinical and regulatory milestone payments up to $25.0 million payable to ActiveSite.” |
Quoted from the company's 10-K filed Sep 24, 2026.
RZLT company outlook (results filed Sep 24, 2026)
- “Enrollment is in progress and topline results are expected before the end of 2026. ·”
Quoted word-for-word from the SEC 8-K results press release.
RZLT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.18 | $-0.15 | −$0.04 | $0 | 8 |
| Next quarter (ends Dec 2026) | $-0.17 | $-0.13 | −$0.04 | $0 | 8 |
| Current fiscal year (ends Jun 2027) | $-0.70 | $-0.63 | −$0.07 | $2.1M | 9 |
| Next fiscal year (ends Jun 2028) | $-0.47 | $-0.28 | −$0.19 | $54.1M | 7 |
Key Statistics (as of October 29, 2026 at 07:33 UTC)
| Price | USD 4.22 |
|---|---|
| Change | ▲ 2.68% (up) |
| Previous Close | USD 4.11 |
| Open | USD 4.11 |
| Day Range | USD 4.02 – 4.24 |
| 52-Week Range | USD 1.07 – 11.46 |
| Volume | 1,414,466 shares |
| Market Cap | $408.17M |
| Exchange | NCM |
Technical Analysis (RZLT)
Nexqual's technical model rates RZLT "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 07:33 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.43 (neutral) |
| vs SMA50 | Below (USD 4.28) |
| MACD | -0.09 (negative) |
Analyst Ratings (RZLT)
Wall Street analysts rate RZLT "Buy" based on 11 analysts, with a mean price target of USD 9.8 (range USD 6–15), per Nexqual as of October 29, 2026 at 07:33 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 9.8 |
| High Target | USD 15 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (RZLT)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.2 vs est -0.14 ▼ miss |
| 2025-12-31 | USD -0.22 vs est -0.18 ▼ miss |
| 2025-09-30 | USD -0.18 vs est -0.26 ▲ beat |
Source: Nexqual, October 29, 2026 at 07:33 UTC.
Financials & Fundamentals (RZLT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -59.04% |
| Debt / Equity | 0.01 |
| Current Ratio | 9.68 |
| Total Cash | $107.80M |
| Total Debt | $934,000 |
Source: Nexqual, October 29, 2026 at 07:33 UTC.
Financial Health Score (RZLT)
Nexqual rates Rezolute, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 07:33 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $108M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$65M (FY ended Jun 2026, 10-K) |
| Efficiency | Critical — ROE -77%, ROA -68.8% (last 4 quarters, SEC) |
Ownership (RZLT)
| Insider Ownership | +10.03% |
|---|---|
| Institutional Ownership | +98.71% |
| Shares Outstanding | 96.72M |
| Float | 60.77M |
| Short % of Float | +25.79% |
Source: Nexqual, October 29, 2026 at 07:33 UTC.
Leadership (RZLT)
Rezolute, Inc. is led by Nevan Charles Elam, Founder, CEO & Acting Chairman of the Board, per Nexqual as of October 29, 2026 at 07:33 UTC.
| Founder, CEO & Acting Chairman of the Board | Nevan Charles Elam |
|---|---|
| Chief Financial & Business Officer | Daron G. Evans M.B.A., M.S. |
| Director and Head of Scientific & Patient Affairs | Davelyn Eaves Hood |
| Senior Director of People and Culture | Melissa Quinn |
Major Backers & Investors (RZLT)
Notable institutional backers of Rezolute, Inc. include Siren, L.L.C., Jacobs Levy Equity Management, Inc., Jennison Associates LLC, according to Nexqual as of October 29, 2026 at 07:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Siren, L.L.C. | 39.54% |
| Jacobs Levy Equity Management, Inc. | 30.43% |
| Jennison Associates LLC | 29.21% |
| Fidelity | 15.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 45.57% |
| Geode Capital | 25.78% |
Source: Nexqual, October 29, 2026 at 07:33 UTC.
From Rezolute, Inc.'s Latest SEC 10-K Filing (filed 2026-09-24)
Key Strengths & Strategy (as disclosed to the SEC)
- We incurred approximately $53.8 million and $61.5 million in research and development expenses for the fiscal years ended June 30, 2026 and 2025, respectively.
Legal & Regulatory Risks (Item 1A, quoted)
- Adverse events in our clinical trials may force us to stop development of our product candidates or prevent regulatory approval of our product candidates.
- Failure of our clinical trials could expose us to litigation and other legal claims, which could materially and adversely affect our business, financial condition and results of operations.
- We face potential product liability exposure, and, if successful claims are brought against us, we may incur substantial liability.
- Litigation regarding patents, patent applications and other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing product candidates to market and harm our ability to operate.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:33 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt